{"groups":[{"description":"Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRituximab: Given IV","id":"FG000","title":"Treatment (Ixazomib Citrate, Rituximab)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)"},{"achievements":[{"groupId":"FG000","numSubjects":"21"}],"type":"Follicular Lymphoma (FL)"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"Marginal Zone Lymphoma (MZL)"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"Mantle Cell Lymphoma (MCL)"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL)"},{"achievements":[{"groupId":"FG000","numSubjects":"5"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"28"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}